CB Insight Digital Health 50, Neuralink Adds A Robotic Arm, & Why MDs Should Care About 340B

Hey all,

Today we’re talking about innovators in healthcare technology and a little bit of 340B. I’m especially excited about Neuralink’s new robotic arm study, although I am a little worried that Neuralink’s tech eventually becomes the Borg. Enjoy the rundown!

Jacob Brody (Co-Founder & CEO, ZorroCard)

Digital Health 50 (CB Insights)

The 2024 Digital Health 50 highlights the most promising private digital health startups globally, emphasizing AI-driven infrastructure, next-gen diagnostics, and hybrid care models. Key trends include AI integration across 36 companies, a surge in virtual and condition-specific care platforms, advancements in non-invasive diagnostics, and workflow automation addressing provider shortages. Noticeably absent from the list are any health insurers or other payers. Full Article.

Elon Musk’s Neuralink Connects Brain To Robotic Arm (MobiHealthNews)

Neuralink announced its CONVOY study to test the N1 brain implant’s ability to control robotic arms, aiming to restore physical freedom for quadriplegic patients. The technology interprets neural activity to control devices, with initial results enabling hands-free tasks like playing games. This follows Neuralink’s ongoing advancements in brain-computer interfaces, including FDA breakthrough designations for related implants. Full Article.

Why Physicians Should Care About 340B (Medscape)

Dr. Madelaine Feldman highlights concerns over the 340B Drug Pricing Program’s misuse, with hospitals profiting from discounted drugs while independent practices face unfair competition. Feldman, known for exposing PBM issues, notes that 78% of program spending benefits disproportionate share hospitals, which often fail to demonstrate how they aid low-income patients. She warns of escalating healthcare consolidation and reduced access to care. The Coalition of State Rheumatology Organizations advocates for reform to restore 340B’s original mission. Full Article.